ATE470441T1 - Modulator der menschlichen mastzellaktivierung - Google Patents

Modulator der menschlichen mastzellaktivierung

Info

Publication number
ATE470441T1
ATE470441T1 AT98917959T AT98917959T ATE470441T1 AT E470441 T1 ATE470441 T1 AT E470441T1 AT 98917959 T AT98917959 T AT 98917959T AT 98917959 T AT98917959 T AT 98917959T AT E470441 T1 ATE470441 T1 AT E470441T1
Authority
AT
Austria
Prior art keywords
mast cell
purinoceptors
cell activation
modulator
atp binding
Prior art date
Application number
AT98917959T
Other languages
German (de)
English (en)
Inventor
Amir Pelleg
Edward Schulman
Original Assignee
Duska Scient Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duska Scient Co filed Critical Duska Scient Co
Application granted granted Critical
Publication of ATE470441T1 publication Critical patent/ATE470441T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Amplifiers (AREA)
AT98917959T 1997-03-25 1998-03-24 Modulator der menschlichen mastzellaktivierung ATE470441T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4146197P 1997-03-25 1997-03-25
PCT/US1998/005922 WO1998042353A1 (en) 1997-03-25 1998-03-24 Modulation of human mast cell activation

Publications (1)

Publication Number Publication Date
ATE470441T1 true ATE470441T1 (de) 2010-06-15

Family

ID=21916643

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98917959T ATE470441T1 (de) 1997-03-25 1998-03-24 Modulator der menschlichen mastzellaktivierung

Country Status (9)

Country Link
US (2) US6372724B1 (https=)
EP (1) EP1011686B9 (https=)
JP (1) JP2001518118A (https=)
AT (1) ATE470441T1 (https=)
AU (1) AU741713B2 (https=)
CA (1) CA2288821C (https=)
DE (1) DE69841711D1 (https=)
DK (1) DK1011686T3 (https=)
WO (1) WO1998042353A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1011686T3 (da) * 1997-03-25 2010-10-11 Duska Scient Co Modulering af human mastcelleaktivering
EP1187617B1 (en) * 1999-06-18 2004-03-03 Alcon Manufacturing Ltd. Method for selecting the concentration of an amphipathic antihistamine drug by determining the drug's surface activity rating
GB9916757D0 (en) * 1999-07-17 1999-09-15 Glaxo Group Ltd Method
US20030166568A1 (en) * 2000-03-23 2003-09-04 Franz Kricek Organic compounds
JP2004520348A (ja) * 2001-01-15 2004-07-08 グラクソ　グループ　リミテッド Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジン誘導体
JP2004520347A (ja) * 2001-01-15 2004-07-08 グラクソ　グループ　リミテッド Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体
WO2002055495A1 (en) * 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine derivatives as inducers of ldl-receptor expression
JP2005532254A (ja) * 2001-11-06 2005-10-27 インスパイアー ファーマシューティカルズ，インコーポレイティド 炎症性疾患を治療又は予防する方法
US7378492B2 (en) * 2002-02-20 2008-05-27 Incyte Corporation CD40-related receptor that binds CD40L
US20070276126A1 (en) * 2002-08-13 2007-11-29 Incyte Corporation Cell adhesion and extracellular matrix proteins
US20070219353A1 (en) * 2002-09-03 2007-09-20 Incyte Corporation Immune Response Associated Proteins
AU2003279829A1 (en) * 2002-10-04 2004-05-04 Incyte Corp Protein modification and maintenance molecules
AU2003300785A1 (en) * 2002-11-12 2004-06-03 Incyte Corporation Carbohydrate-associated proteins
AU2003295462A1 (en) * 2002-11-13 2004-06-03 Incyte Corporation Lipid-associated proteins
AU2003302234A1 (en) * 2002-11-26 2004-06-18 Incyte Corporation Immune response associated proteins
US7829682B1 (en) 2003-04-30 2010-11-09 Incyte Corporation Human β-adrenergic receptor kinase nucleic acid molecule
JP2008507368A (ja) * 2004-07-22 2008-03-13 デュスカ サイエンティフィック カンパニー 肺疾患を診断、モニタリングおよび治療するための方法
AU2006261599B2 (en) 2005-06-24 2011-10-06 The Walter & Eliza Hall Institute Of Medical Research Therapeutic pro-apoptotic BH3-like molecules and methods for generating and/or selecting the same
GB0601058D0 (en) * 2006-01-19 2006-03-01 Univ Southampton Mast Cell Carboxypeptidase As A Marker For Anaphylaxis And Mastocytosis
KR20100015578A (ko) * 2007-03-14 2010-02-12 시에라 몰레큘러 코포레이션 세포 및/또는 거대분자의 보존 및/또는 안정화를 위한 조성물, 시스템 및 방법
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
US10107795B2 (en) 2012-10-25 2018-10-23 The United States Of America As Represented By The Department Of Veterans Affairs Composition and methods for the prevention and treatment of diet-induced obesity
US10614684B2 (en) 2017-01-31 2020-04-07 The United States Government As Represented By The Treatment of kidney diseases associated with elevated AVP

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53148539A (en) * 1977-05-30 1978-12-25 Fujisawa Pharmaceut Co Ltd Antiallergic agnet
US5158940A (en) * 1990-02-14 1992-10-27 The United States Government As Represented By The Secretary, Dhhs Use of suramin to treat rheumatologic diseases
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
AU2566595A (en) * 1994-05-27 1995-12-21 Glaxo Group Limited P-2x receptors (purinoceptor family)
US5733916A (en) * 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
US5874420A (en) 1995-12-26 1999-02-23 Allegheny University Of The Health Sciences Process for regulating vagal tone
DK1011686T3 (da) * 1997-03-25 2010-10-11 Duska Scient Co Modulering af human mastcelleaktivering

Also Published As

Publication number Publication date
DK1011686T3 (da) 2010-10-11
EP1011686A1 (en) 2000-06-28
EP1011686B1 (en) 2010-06-09
CA2288821A1 (en) 1998-10-01
CA2288821C (en) 2008-10-14
US6372724B1 (en) 2002-04-16
WO1998042353A1 (en) 1998-10-01
AU741713B2 (en) 2001-12-06
DE69841711D1 (de) 2010-07-22
EP1011686A4 (en) 2003-03-19
AU7098598A (en) 1998-10-20
EP1011686B9 (en) 2011-02-09
JP2001518118A (ja) 2001-10-09
US20020055515A1 (en) 2002-05-09
US6465441B2 (en) 2002-10-15

Similar Documents

Publication Publication Date Title
ATE470441T1 (de) Modulator der menschlichen mastzellaktivierung
DE69535328D1 (de) In-vitro wachstum von langerhans'schen inseln und ihre verwendungen
ATE510551T1 (de) Hemmung von gs-fdh zur modulierung der no- bioaktivität
AU2002345497A1 (en) Cips as modifiers of the p53 pathway and method of use
WO2002099075A3 (en) Prmts as modifiers of the p53 pathway and methods of use
TR199902803T2 (xx) VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
PT1017692E (pt) 4-heteroaril-tetrahidroquinolinas e sua aplicacao como inibidores da proteina de transferencia de ester de colesterol (ctep)
WO2003103575A3 (en) Compounds, compositions, and methods
ATE398464T1 (de) Synergie zwischen apo-2 ligand und antikörper gegen her-2
DE50015700D1 (de) Substituierte indole zur modulierung von nfkb-aktivität
ATE413386T1 (de) Ppar-gamma modulatoren
DE69620458D1 (de) Benzofuran-carboxamide und -sulfonamide
ATE352639T1 (de) Antisense modulation der expression von integrin alpha 4
DE69835288D1 (de) Kombinationstherapie zur modulation der humanen sexualreaktion
PL367287A1 (en) Use of proteasome inhibitors to treat dry eye disorders
NO20052267L (no) Forbindelser, Preparater og Metoder
NZ503372A (en) Chemical supplementation of bone by exposing bone to a therapeutic compound and applying a potential difference across the bone or tissue
ATE342062T1 (de) Angiotensin ii zur verbesserung der befruchtung
DK1185621T3 (da) Overflade til cellekultur
ES2039578T3 (es) Procedimiento para producir mercapto-acilaminoacidos antihipertensivos.
WO2004053144A3 (en) Modulation of stem cell differentiation by modulation of caspase-3 activity
MXPA02004699A (es) Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco.
WO2003049683A3 (en) Use of parapox b2l protein to treat cancer and modify immune responses
NZ515727A (en) Aminotetralin derivative for the therapy of cardiovascular diseases
DE60028750D1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren